Amyotrophic Lateral Sclerosis Clinical Trials

45 studies are recruiting for amyotrophic lateral sclerosis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

   In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in participant who have a mutation in the superoxi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mass General Hospital -MGH, Boston, Massachusetts

   Run by

   Biogen

   See if you can join NCT07259980 on ClinicalTrials.gov

2. Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth

   Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease in which motor neuron cells of the brain and spinal cord progressively degenerate and die. There is currently a lack of curative treatment for individuals that are diagnosed with ALS. Since treatment options are limited, resea…

   Stage

   Not phased

   Ages

   18 and older

   Site

   TidalHealth Peninsula Regional, Inc., Salisbury, Maryland

   Run by

   TidalHealth, Inc.

   See if you can join NCT07491484 on ClinicalTrials.gov

3. Clinical Research in ALS Study

   CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT00136500 on ClinicalTrials.gov

4. The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study

   Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. The investigators aim to recruit unaffected (healthy) people from familial ALS (fALS) pedigrees in which a known genetic mutation associated with ALS ha…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT00317616 on ClinicalTrials.gov

5. Spinal Cord Associative Plasticity for ALS

   Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen weakened nerve circuits between the brain and hand muscles in people w…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   James J. Peters VA Medical Center, Bronx, NY, The Bronx, New York

   Run by

   VA Office of Research and Development

   See if you can join NCT06172621 on ClinicalTrials.gov

6. Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

   This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses …

   Stage

   Not phased

   Ages

   18 and older

   Site

   NextGen Precision Health Building, Clinical and Translational Science Unit, Columbia, Missouri

   Run by

   University of Missouri-Columbia

   See if you can join NCT07478172 on ClinicalTrials.gov

7. Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

   Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The fo…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Pharmaron, Inc., Baltimore, Maryland

   Run by

   PRG Science & Technology Co., Ltd.

   See if you can join NCT07221240 on ClinicalTrials.gov

8. Assessing Perceptual Effects of Interactive Tasks

   In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across interactive and non-interactive contexts with an unfamiliar, naive interlocutor.

   Stage

   Not phased

   Ages

   18 to 65

   Site

   Speech Core, Pennsylvania State University, University Park, Pennsylvania

   Run by

   Penn State University

   See if you can join NCT06828523 on ClinicalTrials.gov

9. Intermuscular Coherence as a Biomarker for ALS

   The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria),…

   Stage

   Not phased

   Ages

   20 to 90

   Site

   University of Miami Miller School of Medicine, Miami, Florida

   Locations

   4 in total

   Run by

   University of Chicago

   See if you can join NCT05104710 on ClinicalTrials.gov

10. Precise Robotically IMplanted Brain-Computer InterfacE

    The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rechargeable implant co…

    Stage

    Not phased

    Ages

    22 to 75

    Site

    Barrow Neurological Institute, Phoenix, Arizona

    Locations

    2 in total

    Run by

    Neuralink Corp

    See if you can join NCT06429735 on ClinicalTrials.gov

11. Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders

    The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS) patients.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT05116943 on ClinicalTrials.gov

12. Imaging Biomarkers in ALS

    The purpose of the study is to determine if we are able to find one or more biomarkers of Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS) using magnetic resonance imaging (MRI) scans at different levels, 3 tesla (3T) and 7 tesla (7T). A biomarker is a measurable characterist…

    Stage

    Not phased

    Ages

    21 to 75

    Site

    University of Minnesota, Minneapolis, Minnesota

    Run by

    University of Minnesota

    See if you can join NCT02567136 on ClinicalTrials.gov

13. Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

    The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.

    Stage

    Not phased

    Ages

    18 to 80

    Site

    University of California, Davis, Sacramento, California

    Run by

    Leigh R. Hochberg, MD, PhD.

    See if you can join NCT06094205 on ClinicalTrials.gov

14. Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

    The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Am…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Barrow Neurological Institute, Phoenix, Arizona

    Locations

    12 in total

    Run by

    Target ALS Foundation, Inc.

    See if you can join NCT05137665 on ClinicalTrials.gov

15. VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration

    The VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with severe and irrever…

    Stage

    Not phased

    Ages

    22 to 75

    Site

    The University of Texas Southwestern Medical Center, Dallas, Texas

    Run by

    Neuralink Corp

    See if you can join NCT07224256 on ClinicalTrials.gov

16. Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

    The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

    Stage

    Phase 3

    Ages

    18 to 81

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    56 in total

    Run by

    AB Science

    See if you can join NCT03127267 on ClinicalTrials.gov

17. AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

    The UAB Institute for Arts In Medicine (AIM) is currently implementing an expressive emotional writing pilot project for adults with paralysis caused by neurological conditions such as traumatic head or spinal cord injury.

    Stage

    Not phased

    Ages

    18 and older

    Site

    354 School of Health Professions Building, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT04721717 on ClinicalTrials.gov

18. RAPA-501 Therapy for ALS

    RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Rapa Therapeutics LLC

    See if you can join NCT04220190 on ClinicalTrials.gov

19. ALS Research Collaborative

    The goal of this natural history study is to learn more about the biological and clinical aspects of amyotrophic lateral sclerosis (ALS). This study's findings will help with drug discovery, biomarker discovery, and outcome measure validation. Adults living with ALS, other motor neuron diseases (MN…

    Stage

    Not phased

    Ages

    18 and older

    Site

    ALS Therapy Development Institute, Watertown, Massachusetts

    Run by

    ALS Therapy Development Institute

    See if you can join NCT06885918 on ClinicalTrials.gov

20. NYSCF Scientific Discovery Biobank

    The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store th…

    Stage

    Not phased

    Ages

    0 and older

    Site

    New York Stem Cell Foundation Research Institute, New York, New York

    Run by

    New York Stem Cell Foundation Research Institute

    See if you can join NCT06203106 on ClinicalTrials.gov